2492. Differences between Individuals Currently Taking Integrase Inhibitor (INSTI)-based Therapy and Those Not Taking INSTIs in the Era of INSTIs as Recommended First-line Therapy

BACKGROUND: Agents from the integrase inhibitor (INSTI) therapeutic class only are recommended as initial therapy for most patients with HIV. Clinicians now face a decision when treating ART-experienced patients on non-INSTI regimens: continue current therapy or switch to INSTI. Multiple factors may...

Descripción completa

Detalles Bibliográficos
Autores principales: Monroe, Anne K, Levy, Matthew E, Greenberg, Alan E, Moore, Richard, Keruly, Jeanne, Horberg, Michael A, Mohanraj, Bernadine, Kumar, Princy, Castel, Amanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810575/
http://dx.doi.org/10.1093/ofid/ofz360.2170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810575/
http://dx.doi.org/10.1093/ofid/ofz360.2170

Ejemplares similares